Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles
Catherine Z. Chen(National Institutes of Health), Gary R. Whittaker(Cornell University), Joshua Zimmerberg(National Institutes of Health), Wei Zheng(Liaoning Cancer Hospital & Institute), Carleen Klumpp‐Thomas(National Institutes of Health), Kirill Gorshkov(National Center for Advancing Translational Sciences), Sam Michael(National Institutes of Health), Wei Zhu(Guangzhou University of Chinese Medicine), Marco R. Straus(Cornell University), Min Shen(Kaili University), Jennifer D. Petersen(National Institutes of Health), Miao Xu(Shandong University), Hui Guo(First Affiliated Hospital of Xi'an Jiaotong University), Paul Shinn(National Institutes of Health), Manisha Pradhan(National Institutes of Health)
Cited by 128
Related Papers
Human Pluripotent Stem Cell-Derived Neural Cells and Brain Organoids Reveal SARS-CoV-2 Neurotropism Predominates in Choroid Plexus Epithelium
|Cell stem cell|2020|460
Inhibition of the Mitochondrial Protease ClpP as a Therapeutic Strategy for Human Acute Myeloid Leukemia
|Cancer Cell|2015|348
Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
|Science Translational Medicine|2019|259
Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs
|Emerging Microbes & Infections|2014|242
Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening
|ACS Pharmacology & Translational Science|2020|225